14 KIT
Dexcom Follow app. For more details,
CLICK HERE.
Dexcom
This summer, Dexcom plans to launch
a new continuous glucose monitor
for people in the US with Type 2
diabetes who don't take insulin. The
device, called Stelo, was submitted
to the Food and Drug Administration
for review in the fourth quarter of
2023. It will be based on its G7 CGM.
The sensor will last for 15 days and
will have custom software features
tailored to people who do not take
insulin - for example, it will not have
the alerts and the alarms that are
offered with the G6 or G7. Dexcom
will offer this as a cash-pay product:
the price has not yet been disclosed,
but the company hopes to gain
insurance coverage for the device
in America. For more details, CLICK
HERE.
Embecta
Also in the US, Embecta has
announced that it submitted a
filing to the FDA for its proprietary,
disposable insulin patch pump for
people with Type 2 diabetes. The
company describes the pump as
being convenient and discreet,
featuring a 300-unit insulin reservoir,
and has been designed to lighten
the burden of managing diabetes
while improving user outcomes. Its
development has been informed
by the 'unique needs' of people
with Type 2 diabetes and their
healthcare providers. The majority
of automated insulin delivery
systems cater to those with Type
1 diabetes, but Embecta's initiative
aims to offer more options and
tools to the broader Type 2 diabetes
care community. For more details,
CLICK HERE.
Medtronic
Medtronic has announced that it has
received European CE mark approval
for its MiniMed 780G system with
Simplera Sync. The MiniMed 780G
automated insulin delivery system
offers 'meal detection technology'
and provides automatic adjustments
and corrections to blood glucose
levels every five minutes based on the
paired Simplera CGM sensor. It works
for both basal (background) and
bolus (mealtime) insulin needs and
accounts for when users forget to
bolus or underestimate the number
of carbs in their meal. It also requires
no fingersticks when in SmartGuard
mode. With the world's only sevenday
infusion set, MiniMed 780G offers
low glucose target settings (as low as
100 mg/dL).
The Simplera Sync, a nextgeneration
disposable, all-in-one
continuous glucose monitor (CGM),
was launched with InPen in Europe
last year after earning the CE mark,
and is claimed to eliminate the need
for fingersticks and overtape. It
features an improved user experience
at half the size of previous Medtronic
sensors with a simple, two-step
insertion process. Medtronic plans
to make the MiniMed 780G with
Simplera Sync available in Europe
through a limited release in the
spring of 2024 and expects a phased
commercial launch in the summer
of 2024.
Meanwhile, Medtronic has
scrapped its plans to buy insulin
patch-pump maker EOFlow,
which has been sued by Insulet
for patent infringement, citing
'multiple breaches' of the companies'
agreements. For more details,
CLICK HERE.
Tandem
Tandem Diabetes Care has launched
updated t:slim X2 insulin pump
software with Dexcom G7 Continuous
Glucose Monitoring (CGM)
integration in the USA. Tandem's
highly-rated automated insulin
delivery (AID) system with Control-IQ
technology is currently the only AID
option in the world to use Dexcom's
latest CGM technology.
t:slim X2 pumps pre-loaded
with the updated software are
now shipping to new customers,
and Tandem will also be emailing
instructions to all in-warranty t:slim
X2 users in the USA to offer the
option to add the new feature free of
charge via remote software update.
With the integration of Dexcom G7,
t:slim X2 insulin pump users can
now(a) spend more time in closed
loop with little to no wait time
between Dexcom G7 CGM sensor
sessions and (b) use either a Dexcom
G6 or Dexcom G7 CGM sensor,
allowing even more choice in their
diabetes management.
The t:slim X2 pump with Dexcom
G7 integration is expected to launch
in additional countries outside the
USA in early 2024. For more details,
CLICK HERE.
W
te
th
a
tr
re
o
ty
b
si
£
e
w
fli
th
lo
n
E
U
T